Cargando…

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients

The latest literature demonstrates the predominant role of the programmed cell death axis (PD-1/PD-L1/PD-L2) in ovarian cancer (OC) pathogenesis. However, data concerning this issue is ambiguous. Our research aimed to evaluate the clinical importance of PD-L1/PD-L2 expression in OC environments. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawłowska, Anna, Kwiatkowska, Agnieszka, Suszczyk, Dorota, Chudzik, Agata, Tarkowski, Rafał, Barczyński, Bartłomiej, Kotarski, Jan, Wertel, Iwona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583913/ https://www.ncbi.nlm.nih.gov/pubmed/34768993 http://dx.doi.org/10.3390/ijms222111563

Ejemplares similares

Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer
por: Wertel, Iwona, et al.
Publicado: (2020)

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2020)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy
por: Bilska, Monika, et al.
Publicado: (2020)

Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2023)

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer
por: Parafiniuk, Klaudia, et al.
Publicado: (2022)

Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancer—State-of-the-Art
por: Skiba, Wiktoria, et al.
Publicado: (2022)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art
por: Suszczyk, Dorota, et al.
Publicado: (2021)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
por: Pawłowska, Anna, et al.
Publicado: (2023)

Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer
por: Okła, Karolina, et al.
Publicado: (2019)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Low-Density Lipoproteins Oxidation and Endometriosis
por: Polak, Grzegorz, et al.
Publicado: (2013)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
por: Walankiewicz, Monika, et al.
Publicado: (2018)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
por: Surówka, J., et al.
Publicado: (2017)

γδ T Lymphocytes as a Double-Edged Sword—State of the Art in Gynecological Diseases
por: Pawłowska, Anna, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
por: Wertel, I., et al.
Publicado: (2015)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
por: Fan, Yangwei, et al.
Publicado: (2016)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis
por: Adamczyk, Michał, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
por: Kim, Hae Su, et al.
Publicado: (2016)

PD-1/PD-L1 and DNA Damage Response in Cancer
por: Kciuk, Mateusz, et al.
Publicado: (2023)

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review
por: Adamczyk, Michał, et al.
Publicado: (2022)

Gender Dysphoria Disrupting the Course of Treatment of a Recurrent Juvenile Granulosa Cell Tumor in an Adolescent Female: A Case Report
por: Kwiatkowska, Agnieszka, et al.
Publicado: (2020)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours
por: Rösner, Erik, et al.
Publicado: (2021)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a2skjj06r0vk3mrg84af5c0ugt